IMPACT THERAP-B (07630) Executive Director and CEO Cai Suixiong increased his holding by 100,000 shares.

date
08:09 03/09/2026
avatar
GMT Eight
Inpa Pharmaceuticals-B (07630) announced that the board of directors was informed by Dr. Cai Suixiong, the company's executive director and CEO, that he recently purchased a total of 100,000 shares of the company's ordinary stock on the open market, with an average price per share of approximately HKD 14.6105, accounting for about 0.035% of the company's total issued shares. Following this purchase, Dr. Cai holds an interest in a total of 18,540,900 shares, representing approximately 6.564% of the total issued share capital of the company as of the date of this announcement.
IMPACT THERAP-B (07630) has announced that the Board of Directors has been informed by Dr. Cai Suixiong, the company's Executive Director and Chief Executive Officer, that he has recently purchased a total of 100,000 ordinary shares of the company on the open market, at an average price of approximately HKD 14.6105 per share, representing about 0.035% of the total issued shares of the company. Following this purchase, Dr. Cai owns rights in a total of 18,540,900 shares, which represents approximately 6.564% of the total issued share capital of the company as of the date of this announcement. In addition, Dr. Cai expressed his confidence in the overall development prospects and potential growth of the Group. In compliance with applicable laws and regulatory requirements, Dr. Cai does not rule out the possibility of further increasing his stake in the company at the appropriate time.